Clinical trial Recruiting at 1 site Observational Ages 18 to 60

Comparing protein patterns in extracellular vesicles from different blood vessels in people with ruptured or unruptured brain aneurysms

Official title: Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions

Run by The First Hospital of Jilin University · NCT07439965 · Data updated 2026-11-12

This project tries to see if protein differences in extracellular vesicles taken from different blood vessels can help diagnose or predict outcomes for people with ruptured or unruptured brain aneurysms undergoing neurointerventional procedures.

Quick facts

Study typeObservational
Ages18 Years to 60 Years
SexAll
Enrollment120 (estimated)
SponsorThe First Hospital of Jilin University
Academic / other
Locations1 site (Changchun, Jilin)
StatusRecruiting
StartedJuly 29, 2025
Main results expectedApril 2026
Study endsJune 2026
Registry record updatedFebruary 27, 2026
Trial IDNCT07439965 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–60 with a confirmed intracranial aneurysm who are scheduled for neurointerventional treatment under general anesthesia (ruptured cases sampled within three days) and who can give informed consent.

Probably not a fit

People older than 60, those with significant preexisting neurological or systemic diseases, a baseline mRS ≥2, or those not undergoing neurointervention are unlikely to be eligible or benefit from this observational protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will collect blood during neurointerventional procedures from the femoral vein, internal jugular vein, and internal carotid artery of adults with ruptured or unruptured intracranial aneurysms. Extracellular vesicles will be isolated from those samples and analyzed with proteomic methods to map protein differences across vascular locations and between hemorrhagic and non-hemorrhagic cases. The study focuses on patients aged 18–60 who are undergoing treatment under general anesthesia, with ruptured cases sampled within three days of symptom onset. As an observational project, there is no treatment intervention; findings aim to identify candidate EV-derived protein biomarkers linked to diagnosis and prognosis.

Why it matters

Potential benefit: If successful, this work could identify blood-based protein markers from specific vascular sites that improve diagnosis and prognosis after subarachnoid hemorrhage.

How similar studies have gone: Prior studies have identified diagnostic signals in extracellular vesicles from peripheral blood, but sampling proteomic heterogeneity across head and neck arterial and venous sites during neurointervention is a novel approach that has not yet been validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\. Aged between 18 and 60 years, regardless of gender; 2. Diagnosed with intracranial aneurysm confirmed by MRA, CTA, or DSA; 3. Patients with aneurysmal subarachnoid hemorrhage must have CT imaging evidence of hemorrhage, and blood collection must occur within 3 days of symptom onset; 4. Scheduled to undergo neurointerventional surgery for intracranial aneurysm under general anesthesia, with the procedure starting between 8:00 AM and 12:00 PM; 5. Willing to comply with the study protocol and data collection procedures; 6. Able to understand and sign the informed consent form.

Exclusion Criteria:

* 1\. Patients with a pre-onset (in hemorrhagic cases) or preoperative (in non-hemorrhagic cases) Modified Rankin Scale (MRS) score ≥ 2; 2. Presence of other neurological disorders such as Parkinson's disease, Alzheimer's disease, cerebral infarction, brain tumors, epilepsy, etc.; 3. Presence of other systemic diseases such as diabetes, coronary artery disease, cancer, infections, hematological diseases, or severe metabolic disorders that may significantly affect the evaluation of blood EVs; 4. History of severe hepatic or renal dysfunction (ALT \> 3 times the upper limit of normal; creatinine \> 225 μmol/L); 5. Patients who cannot tolerate anesthesia, anticoagulant therapy, or who have coagulation disorders; 6. History of severe allergic reactions to contrast agents; 7. Pregnant women; 8. Patients participating in other clinical trials who have not yet completed follow-up.

Where it's running

  • First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.